Alogliptin / Metformin
Vipdomet · ATC code A10BD13
Also known as: Alogliptin/Metformin
- Key facts
- Active substance
- Alogliptin / Metformin
- Drug class
- Anti-diabetic medication
- ATC code
- A10BD13
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Vipdomet 12.5 mg/850 mg film-coated tablets / Vipdomet 12.5 mg/1 000 mg film-coated tablets
- Marketing authorisation holder
- Takeda Pharma A/S
- Information as of
- 2026-10-28
Key facts
Alogliptin/metformin is a fixed-dose combination of a DPP-4 inhibitor and a biguanide. It is used in adults with type 2 diabetes to improve glycaemic control.
What it is used for
- Adults aged 18 years and older with type 2 diabetes mellitus, as an adjunct to diet and exercise, when the maximal tolerated dose of metformin alone is insufficient or in patients already treated with alogliptin and metformin (Vipdomet).
- In combination with pioglitazone or with insulin (triple therapy) when previous treatment is insufficient.
Dosing
- Vipdomet is available as 12.5 mg/850 mg and 12.5 mg/1,000 mg film-coated tablets; the dose is based on the current regimen.
- Inadequately controlled on metformin alone: one 12.5 mg/850 mg or 12.5 mg/1,000 mg tablet twice daily (25 mg alogliptin plus 1,700 mg or 2,000 mg metformin hydrochloride daily).
- With pioglitazone or insulin: alogliptin 12.5 mg twice daily and metformin at a dose similar to that already taken; a lower insulin or thiazolidinedione dose may be considered.
- The maximum daily dose of 25 mg alogliptin should not be exceeded.
- Assess GFR before starting and at least annually. GFR 45-59 mL/min: metformin max 2,000 mg, alogliptin max 12.5 mg daily; GFR 30-44 mL/min: metformin max 1,000 mg, alogliptin max 12.5 mg daily; GFR < 30 mL/min: contraindicated. See the full text for details.
- Hepatic impairment: must not be used.
Contraindications
- Hypersensitivity to the active substances or excipients, or history of a serious hypersensitivity reaction to any DPP-4 inhibitor.
- Any acute metabolic acidosis (e.g. lactic acidosis, diabetic ketoacidosis); diabetic pre-coma.
- Severe renal failure (GFR < 30 mL/min) and acute conditions that may alter renal function (dehydration, severe infection, shock).
- Diseases that may cause tissue hypoxia (e.g. cardiac or respiratory failure, recent myocardial infarction), hepatic impairment, acute alcohol intoxication, alcoholism.
Important warnings
- Not for type 1 diabetes; not a substitute for insulin.
- Lactic acidosis (very rare but serious): stop temporarily in dehydration; start medicines that can acutely impair renal function with caution.
- Iodinated contrast agents: stop before or at the time of imaging and do not restart until at least 48 hours after, once renal function is stable.
- Increased risk of hypoglycaemia with insulin or a thiazolidinedione.
- Acute pancreatitis and hypersensitivity reactions are attributed to the alogliptin component. See the full text for further warnings.
Side effects
- Serious: acute pancreatitis, hypersensitivity reactions (Stevens-Johnson syndrome, anaphylactic reactions, angioedema) and lactic acidosis (very rare, < 1/10,000).
- Common: upper respiratory tract infections, nasopharyngitis, headache, gastroenteritis, abdominal pain, diarrhoea, vomiting, gastritis, reflux disease, pruritus, rash, hypoglycaemia.
Interactions
- Alcohol increases the risk of lactic acidosis; concomitant use not recommended.
- Iodinated contrast agents (see warnings).
- Medicines that can acutely impair renal function (e.g. antihypertensives, diuretics, NSAIDs) should be started with caution.
Pregnancy and breastfeeding
- Vipdomet should not be used during pregnancy; for breast-feeding see the full text.
Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
This product has no separate US patient information.
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- VipdometTakeda Pharma A/S · EMEA/H/C/002654
Source: European Medicines Agency (EMA), product information
Brand names in 3 more European countries
- Iceland
- Vipdomet
- Liechtenstein
- Vipdomet
- Norway
- Vipdomet
EMA – Article 57 product data (EU/EEA), 2026-10-29
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Vipdomet – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/vipdomet-epar-product-information_en.pdf
- Wikidata (CC0): ATC A10BD.
Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.